Reset filter
Keywords
Multiple Sclerosis, Relapsing-Remitting ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
    1. 1.1. Eligibility Determination
    1. 1.2. Medical History
    1. 1.3. Physical Examination
    1. 1.4. Assessment Score
    1. 1.5. Apparative Diagnostics
    1. 1.6. Laboratory
    1. 1.7. Pathology/Histology
    1. 1.8. Consent
    1. 1.9. Therapy
    1. 1.10. Operative Report
    1. 1.11. Adverse Event
    1. 1.12. Follow-Up
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

95 Search results.

Relevance Rating New first Old first

Visit 1 (Screening) Part 1/2, DIMAT-MS, Relapsing Remitting Multiple Sclerosis DRKS00008037 NCT02461069 - NON-MS Treatment and symptomatic MS Treatment

- 5/24/16 - 4 forms, 4 itemgroups, 19 items, 1 language
Itemgroups: General Instructions,Medical Examination,Expanded disability status scale (EDSS),Signature
Study documentation part: Visits 1 (Screening), Study week -4 to 0 Study Details: A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on ImmuneModulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis. Principal Investigator PD Dr. Luisa Klotz, University Hospital Münster EudraCT - No.: 2014-003481-25. Clinical Trial No.r: NCT02461069.

Eligibility

3 itemgroups 31 items

Visit 1 (Screening) Part 1/2, DIMAT-MS, Relapsing Remitting Multiple Sclerosis NCT02461069

7 itemgroups 31 items

Blood samples for safety laboratory tests

4 itemgroups 16 items

Screenning: EDSS Multiple Sclerosis ALAIN01 NCT02419378

- 5/31/16 - 1 form, 1 itemgroup, 12 items, 1 language
Itemgroup: EDSS
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Screenning

Eligibility NCT01285401 Relapsing-Remitting Multiple Sclerosis - Eligibility

- 9/27/21 - 1 form, 2 itemgroups, 36 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01285401

Eligibility Multiple Sclerosis, Relapsing-Remitting NCT02419378

- 9/27/21 - 1 form, 2 itemgroups, 48 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential; ODM derived from: https://clinicaltrials.gov/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany

Eligibility Relapsing- Remitting Multiple Sclerosis NCT01842191

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Efficacy of Fish Oil in Multiple Sclerosis; ODM derived from: https://clinicaltrials.gov/show/NCT01842191

Eligibility Multiple Sclerosis, Relapsing-remitting NCT01080001

- 9/20/21 - 1 form, 2 itemgroups, 12 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
A Observational, Prospective Study to Assess the Impact of Fatigue in the Quality of Life of Patients With Multiple Sclerosis in Argentina; ODM derived from: https://clinicaltrials.gov/show/NCT01080001

Eligibility NCT00078338 Multiple Sclerosis - Eligibility

- 9/20/21 - 1 form, 3 itemgroups, 34 items, 2 languages
Itemgroups: Inclusion criteria,Exclusion criteria,Medical Concepts
Rebif(R) Versus Copaxone(R) in the Treatment of Relapsing Remitting Multiple Sclerosis Inclusion Criteria: - Be between 18 and 60 years of age - Have definite relapsing multiple sclerosis - Have had one or more relapses within the prior 12 months - Must be in a clinically stable or improving neurological state during the four weeks prior to Study Day 1 - EDSS score from 0 to 5.5, inclusive - If female, she must either be post-menopausal or surgically sterilized; or use a hormonal contraceptive, intra uterine device, diaphragm with spermicide, or condom with spermicide, for the duration of the study; and be neither pregnant nor breast-feeding - Confirmation that the subject is not pregnant must be established by a negative serum hCG pregnancy test within 7 days of Study Day 1 and a negative urine pregnancy test on Study Day 1. A pregnancy test is not required if the subject is post-menopausal or surgically sterilized - Be willing and able to comply with the protocol for the duration of the study - Voluntarily provide written informed consent and, for USA sites only, a subject authorization under Health Insurance Portability and Accountability Act (HIPAA), prior to any study-related procedure that is not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to their future medical care. Exclusion Criteria: - Have secondary progressive MS or primary progressive MS - Prior use of any interferon or glatiramer acetate - Have had treatment with oral or systemic corticosteroids or ACTH within 4 weeks of Study Day 1 and within 7 days prior to the Day 1 MRI. - Have a psychiatric disorder that is unstable or would preclude safe participation in the study - Have significant leukopenia (white blood cell count < 0.5 times the lower limit of normal of the central laboratory) within 7 days of Study Day 1 - Have elevated liver function tests (AST, ALT, alkaline phosphatase > 2.0 times the upper limit of normal (ULN) of the central laboratory, or total bilirubin > 1.5 times the ULN of the central laboratory) within 7 days of Study Day 1 or a history of hepatitis (including infectious or drug-induced) - Prior cytokine or anti-cytokine therapy within 3 months prior to Study Day 1 - Prior use of immunomodulatory or immunosuppressive therapy (including but not limited to cyclophosphamide, cyclosporin, methotrexate, azathioprine, linomide, mitoxantrone) within the 12 months prior to Study Day 1 - Prior use of cladribine or have received total lymphoid irradiation - Have allergy or hypersensitivity to human serum albumin, mannitol, glatiramer acetate, natural or recombinant interferon-β, or any other components of the study drugs or gadolinium DTPA - Have taken intravenous immunoglobulin or any other investigational drug or taken part in any experimental procedure in the 6 months prior to Study Day 1 - Presence of systemic disease that might interfere with subject safety, compliance or evaluation of the condition under study (e.g. insulin-dependent diabetes, Lyme disease, clinically significant cardiac disease, HIV, HTLV-1) - Have had plasma exchange in 3 months prior to Study Day 1

Eligibility Relapsing Remitting Multiple Sclerosis (RRMS) NCT00428584

- 9/20/21 - 1 form, 2 itemgroups, 25 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
RNF and Betaseron® Tolerability Study; ODM derived from: https://clinicaltrials.gov/show/NCT00428584

Screening: Demography Multiple Sclerosis ALAIN01 NCT02419378

- 9/20/21 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: Demography
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Screening

Eligibility NCT00879658 Relapsing-remitting Multiple Sclerosis - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 10 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT00879658

Eligibility NCT01185821 Relapsing Remitting Multiple Sclerosis - Eligibility

- 9/20/21 - 1 form, 2 itemgroups, 8 items, 2 languages
Itemgroups: Inclusion Criteria,Exclusion Criteria
ODM derived from http://clinicaltrials.gov/show/NCT01185821

Eligibility Relapsing Multiple Sclerosis NCT00472797

- 9/17/21 - 1 form, 2 itemgroups, 23 items, 1 language
Itemgroups: Inclusion Criteria,Exclusion Criteria
Rebif New Formulation (RNF) Quality of Life (QOL) Study; ODM derived from: https://clinicaltrials.gov/show/NCT00472797

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial